Trump Signs Executive Order to Speed Research on Psychedelic Drug Therapies

President Trump signed an executive order in April that speeds up research and increases funding for psychedelic drug therapies. A Democratic congressman from California who is leading a bipartisan effort to advance these therapies appeared on CBS News program "The Takeout" to discuss the order and related legislative work.

The congressman stated that policymakers owe it to veterans to research psychedelic drug therapies. The executive order directs federal agencies to expedite studies into the potential medical uses of psychedelics. It also provides additional resources for clinical trials and related scientific work.

Lawmakers from both parties have supported measures to study psychedelic compounds for conditions including post-traumatic stress disorder and depression. The effort has gained attention as an increasing number of states and localities explore regulated access to such substances for therapeutic purposes.

The discussion on "The Takeout" focused on how the executive order aligns with ongoing congressional work. Supporters argue that rigorous research is needed to determine safety and efficacy before wider adoption.

Research into psychedelic-assisted therapy has shown preliminary promise in small studies for treating trauma-related disorders. Federal funding and regulatory streamlining could accelerate larger trials required for potential approval of new therapies. Officials have not released specific funding amounts or timelines tied to the April order.